Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Open Access
- 1 October 2021
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 2239-2248
Abstract
Purpose: Relapse and treatment adherence to paliperidone palmitate once-monthly (PP1M) and three-monthly (PP3M) formulations in patients with schizophrenia were evaluated and compared using health claims data. Patients and Methods: Data (June 2015─June 2018) obtained from the MarketScan® Multi-State Medicaid Database were retrospectively analyzed. Patients aged ≥ 18 years with ≥ 1 claim for schizophrenia diagnosis prior to and/or at index date (i.e., date of first PP3M prescription record for PP3M patients and same month/year as the matched PP3M patients for PP1M patients) and continuous enrollment in the insurance plan for ≥ 12 months prior to index date (baseline) were included. PP1M cohort included patients who received ≥ 4 PP1M doses. PP3M patients were matched with PP1M patients (1:3) using propensity score matching and prevalent new user design. Outcome measures were relapse rate, time to relapse, proportion of days covered (PDC), and level of treatment adherence defined by PDC in five levels. Time to relapse was compared by Kaplan–Meier survival curves and log-rank test with the hazard ratio calculated using Cox proportion hazards model; PDC by t-test, and relapse rate and PDC categories by chi-square test. Results: A total of 1564 patients (428 PP3M and 1136 PP1M) were included. Relapse rate was lower in PP3M cohort (10.5%) compared with PP1M cohort (15.7%). Incidence rate of relapse was 8.98/100 person-years (PY) in PP3M cohort and 13.81/100 PY in PP1M cohort. After a mean (SD) follow-up of 456.1 (240.28) days in PP3M cohort and 465.4 (237.95) days in PP1M cohort, PP3M patients had a significantly lower relapse risk (hazard ratio: 0.65, 95% CI: 0.47, 0.90) than PP1M patients. Treatment adherence was significantly (p< 0.0001) higher in PP3M versus PP1M cohort. Conclusion: Risk of relapse was significantly lower, and treatment adherence was significantly higher in PP3M cohort compared with PP1M cohort. Higher treatment adherence was associated with lower relapse rate.Keywords
This publication has 35 references indexed in Scilit:
- Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisBMC Psychiatry, 2013
- Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI StudyAmerican Journal of Psychiatry, 2013
- Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTherapeutic Advances in Psychopharmacology, 2013
- Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysisNeuropsychiatric Disease and Treatment, 2013
- Guideline-Concordant Antipsychotic Use and Mortality in SchizophreniaSchizophrenia Bulletin, 2012
- Gray Matter Deficits, Mismatch Negativity, and Outcomes in SchizophreniaSchizophrenia Bulletin, 2009
- Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approachPsychological Medicine, 2006
- Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With SchizophreniaPsychiatric Services, 2004
- Increased suicide attempt rate among patients interrupting use of atypical antipsychoticsPharmacoepidemiology and Drug Safety, 2003
- Cognition in Schizophrenia Natural History, Assessment, and Clinical ImportanceNeuropsychopharmacology, 1999